Bosh sahifaATYR • NASDAQ
add
aTyr Pharma Inc
0,81 $
Seans yopilganidan keyin:(0,47%)-0,0038
0,81 $
Yopilgan:5-noy, 17:30:55 (GMT-5) · USD · NASDAQ · Ogohlantirish
Yopilish kursi
0,83 $
Kunlik diapazon
0,79 $ - 0,83 $
Yillik diapazon
0,68 $ - 7,29 $
Bozor kapitalizatsiyasi
79,80 mln USD
Oʻrtacha hajm
8,90 mln
Narx/foyda
-
Dividend daromadliligi
-
Asosiy maydon
NASDAQ
Yangiliklarda
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (USD) | iyn, 2025info | Y/Y qiyosi |
|---|---|---|
Daromad | — | — |
Joriy xarajat | 4,93 mln | 47,49% |
Sof foyda | -19,53 mln | -19,78% |
Sof foyda marjasi | — | — |
Har bir ulushga tushum | -0,22 | 4,35% |
EBITDA | -20,15 mln | -17,56% |
Amaldagi soliq stavkasi | — | — |
Balans
Jami aktivlari
Jami passivlari
| (USD) | iyn, 2025info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 80,35 mln | 2,38% |
Jami aktivlari | 101,53 mln | -4,16% |
Jami passivlari | 26,88 mln | 9,64% |
Umumiy kapital | 74,66 mln | — |
Tarqatilgan aksiyalar | 97,99 mln | — |
Narxi/balansdagi bahosi | 1,02 | — |
Aktivlardan daromad | -51,09% | — |
Kapitaldan daromad | -57,98% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (USD) | iyn, 2025info | Y/Y qiyosi |
|---|---|---|
Sof foyda | -19,53 mln | -19,78% |
Operatsiyalardan naqd pul | -13,89 mln | 32,06% |
Sarmoyadan naqd pul | 3,30 mln | -50,94% |
Moliyadan naqd pul | 17,90 mln | 33,56% |
Naqd pulning sof oʻzgarishi | 7,30 mln | 2 375,39% |
Boʻsh pul | -6,43 mln | 51,63% |
Haqida
aTyr Pharma is a public biotherapeutics company that is focused on researching the extracellular functionality and signaling pathways of tRNA synthetases.
The company's lead product candidate, ATYR1923, is a selective modulator of Neuropilin-2 that downregulates both the innate and adaptive immune responses in inflammatory disease states. aTyr is developing ATYR1923 as a potential disease-modifying therapy for patients with interstitial lung disease, a group of rare immune-mediated disorders that cause progressive fibrosis of the lung interstitium and remain a high unmet medical need. ATYR1923 is currently being investigated in a clinical trial in pulmonary sarcoidosis patients.
The company was founded in 2005 and is headquartered in San Diego, California, and led by CEO Sanjay S. Shukla. Wikipedia
Tashkil etilgan
1-yan, 2005
Sayt
Xodimlar soni
61
